Recent advances in the biology and therapy of muscle wasting

被引：95

作者：

Glass, David ^{[2
]}

Roubenoff, Ronenn ^{[1
]}

机构：

[1] Novartis Inst Biomed Res, Cambridge, MA 02139 USA

[2] Novartis Inst Biomed Res, Muscle Dis Grp, Cambridge, MA 02139 USA

来源：

MOLECULAR AND INTEGRATIVE PHYSIOLOGY OF THE MUSCULOSKELETAL SYSTEM | 2010年 / 1211卷

关键词：

cachexia; sarcopenia; therapeutics; NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY-VIRUS; SKELETAL-MUSCLE; BODY-COMPOSITION; PROTEIN-DEGRADATION; GENE-EXPRESSION; MYOBLAST DIFFERENTIATION; SIGNALING PATHWAYS; WEAK INDUCER; WEIGHT-LOSS;

D O I：

10.1111/j.1749-6632.2010.05809.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The recent advances in our understanding of the biology of muscle, and how anabolic and catabolic stimuli interact to control muscle mass and function, have led to new interest in pharmacological treatment of muscle wasting. Lots of muscle occurs as a consequence of many chronic diseases (cachexia), as well as normal aging (sarcopenia). Although anabolic effects of exercise on muscle have been know for many years, the development of pharmacological treatment for muscle loss is in its infancy. However, there is growing excitement among researchers in this field that developments may yield new treatments for muscle wasting in the future.

引用

页码：25 / 36

页数：12

共 78 条

[1] Wasting as independent risk factor for mortality in chronic heart failure [J].

Anker, SD ;

Ponikowski, P ;

Varney, S ;

Chua, TP ;

Clark, AL ;

WebbPeploe, KM ;

Harrington, D ;

Kox, WJ ;

PooleWilson, PA ;

Coats, AJS .

LANCET, 1997, 349 (9058) :1050-1053

[2] Cancer-associated cachexia and underlying biological mechanisms [J].

Baracos, Vickie E. .

ANNUAL REVIEW OF NUTRITION, 2006, 26 :435-461

[3] Epidemiology of sarcopenia among the elderly in New Mexico [J].

Baumgartner, RN ;

Koehler, KM ;

Gallagher, D ;

Romero, L ;

Heymsfield, SB ;

Ross, RR ;

Garry, PJ ;

Lindeman, RD .

AMERICAN JOURNAL OF EPIDEMIOLOGY, 1998, 147 (08) :755-763

[4] Skeletal Muscle-Specific Ablation of raptor, but Not of rictor, Causes Metabolic Changes and Results in Muscle Dystrophy [J].

Bentzinger, C. Florian ;

Romanino, Klaas ;

Cloetta, Dimitri ;

Lin, Shuo ;

Mascarenhas, Joseph B. ;

Oliveri, Filippo ;

Xia, Jinyu ;

Casanova, Emilio ;

Costa, Celine F. ;

Brink, Marijke ;

Zorzato, Francesco ;

Hall, Michael N. ;

Rueegg, Markus A. .

CELL METABOLISM, 2008, 8 (05) :411-424

[5] The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men [J].

Bhasin, S ;

Storer, TW ;

Berman, N ;

Callegari, C ;

Clevenger, B ;

Phillips, J ;

Bunnell, TJ ;

Tricker, R ;

Shirazi, A ;

Casaburi, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (01) :1-7

[6] Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo [J].

Bodine, SC ;

Stitt, TN ;

Gonzalez, M ;

Kline, WO ;

Stover, GL ;

Bauerlein, R ;

Zlotchenko, E ;

Scrimgeour, A ;

Lawrence, JC ;

Glass, DJ ;

Yancopoulos, GD .

NATURE CELL BIOLOGY, 2001, 3 (11) :1014-1019

[7] Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men - A Clinical research center study [J].

Brodsky, IG ;

Balagopal, P ;

Nair, KS .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (10) :3469-3475

[8]

Brown Sequard C.E., 1889, Lancet, V134, P105, DOI [DOI 10.1016/S0140-6736(00)64118-1, 10.1016/S0140-6736(00)64118-1.]

[9] IKKβ/NF-κB activation causes severe muscle wasting in mice [J].

Cai, DS ;

Frantz, JD ;

Tawa, NE ;

Melendez, PA ;

Oh, BC ;

Lidov, HGW ;

Hasselgren, PO ;

Frontera, WR ;

Lee, J ;

Glass, DJ ;

Shoelson, SE .

CELL, 2004, 119 (02) :285-298

[10] The E3 ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle [J].

Clarke, Brian A. ;

Drujan, Doreen ;

Willis, Monte S. ;

Murphy, Leon O. ;

Corpina, Richard A. ;

Burova, Elena ;

Rakhilin, Sergey V. ;

Stitt, Trevor N. ;

Patterson, Cam ;

Latres, Esther ;

Glass, David J. .

CELL METABOLISM, 2007, 6 (05) :376-385

← 1 2 3 4 5 6 7 8 →